المؤلفون: NanoCarrier Co., Ltd.

المصدر: A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

الوصول الحر: https://clinicaltrials.gov/show/NCT01999491Test

Other URLs: http://www.mdanderson.orgTest

المساهمون: Andrew Frankart, Principal Investigator

المصدر: A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06416007Test

المصدر: MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400251Test

المصدر: MATCH Treatment Subprotocol Z1H: Phase II Study of Copanlisib in Patients With Tumors With Deleterious PTEN Sequencing Result and PTEN Expression by IHC

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400238Test

المصدر: MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF Mutations

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400225Test

المصدر: MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 Therapy

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06400264Test

المؤلفون: City of Hope Medical Center, Miyarisan Pharmaceuticals, Co., Ltd., National Cancer Institute (NCI)

المصدر: Dman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, CuY, Ma V, Llamas M, Hsu J, Zeng Z, Salg N, Salg S, Malhotra J, Chawla N, ChehrazRaffle A, MuddasanR, Glece J, Reg L, Trent J, TakahashM, Oka K, HashS, KortylewskM, Hhlander SK, Pal SK. Nolumab plus umab wh or whout le bacterl supplementatn metastat renal cell carcoma: a randomed phase 1 trl. Nat Med. 2022 Apr;28(4):704-712. do 10.1038/s41591-022-01694-6. Epub 2022 Feb 28.
Toma Y, eda T, Sakata S, SaruwatarK, Sato R, ama S, JodaT, Akae K, huka S, SaekS, SakagamT. Assoctn of Probt Clostrm butyrum Therapy wh Surval and Response to mune Checkpot Blockade Patnts wh Lung Cancer. Cancer munol Res. 2020 Oct;8(10):1236-1242. do 10.1158/2326-6066.C-20-0051. Epub 2020 Jul 14.
Toma Y, Goto Y, Sakata S, amura K, Memura A, Oka K, HayashA, JodaT, Akae K, AnaM, Hamada S, ama S, SaruwatarK, SaekS, TakahashM, eda T, SakagamT. Clostrm butyrum therapy restores the decreased effacy of mune checkpot blockade lung cancer patnts receg proton pump hors. Oncomunology. 2022 May 27;11(1):2081010. do 10.1080/2162402X.2022.2081010. eCollectn 2022.
Toma Y, Sakata S, amura K, ama S, JodaT, SaruwatarK, Hamada S, Akae K, AnaM, Fukusa K, TakakA, Tsukamoto H, Goto Y, Motozono C, Sugata K, Satou Y, Ueno T, eda T, SakagamT. Assoctn of Clostrm butyrum Therapy Usg the Le Bacterl Product CBM588 wh the Surval of Patnts wh Lung Cancer Receg Chemomunotherapy Combatns. Cancers (Basel). 2023 Dec 21;16(1):47. do 10.3390/cancers16010047.
Paz Del Socorro T, Oka K, Boulard O, TakahashM, Poul LF, HayashA, Chamalard M. The btherapeut Clostrm butyrum MA588 stra potenttes enterotropm of Rorgammat+Treg and PD-1 blockade effacy. Gut Mrobes. 2024 Jan-Dec;16(1):2315631. do 10.1080/19490976.2024.2315631. Epub 2024 Feb 22.
An Open-Label, Phase I, Dose-Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab for Patients With Advanced Stage Renal Cell Carcinoma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06399419Test

المصدر: MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390852Test

المصدر: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390826Test

المصدر: MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT06390865Test